Gabapentin Capsule
Product Images NDC 80425-0286

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0286). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Description (Description)

Description (Description)
FDA Label Image

Label 1 (Gabapentin 80425 0286 01)

Label 1 (Gabapentin 80425 0286 01)
FDA Label Image

Label 2 (Gabapentin 80425 0286 02)

Label 2 (Gabapentin 80425 0286 02)
This is a description of a medication called "Gabapentin 400mg capsule". It has a National Drug Code (NOC) of 80325-0286-02 and a source NOC of 69367-0345-05. The medication comes in a lot XXROMHX with an expiry date of 4/3/2024. The serial number of this specific medication is 000000135503.*
FDA Label Image

Label 3 (Gabapentin 80425 0286 03)

Label 3 (Gabapentin 80425 0286 03)
This is a description of a medication package of Gabapentin 400mg capsules, with 90 capsules in the pack. The lot number is XKK and the expiration date is 4/3/2024. The package was packed by Advanced and there is a serial number mentioned as well.*
FDA Label Image

Fig 1 (Fig 1)

Fig 1 (Fig 1)
The text presents a chart showing the Mean Pain Score during a period of d-Week Dose Titration followed by a 4-Week Fixed Dose. The chart displays the results from baseline to week 7 comparing the Placebo group to the Gabapentin group, which received a dose of 3,600 mg/day.*
FDA Label Image

Fig 2 (Fig 2)

Fig 2 (Fig 2)
The text suggests the presentation of results related to a clinical trial that measured pain score. The trial had two periods, a 3-week flexible dose titration phase followed by a 4-week fixed-dose period. The results include the comparison of placebo to two different doses of Gabapentin. However, without knowing the unit of measurement or any other information, it is not possible to infer the impact of Gabapentin on reducing pain.*
FDA Label Image

Fig 3 (Fig 3)

Fig 3 (Fig 3)
FDA Label Image

Fig 4 (Fig 4)

Fig 4 (Fig 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.